EC Number |
Inhibitors |
Structure |
---|
2.3.1.30 | (1aR,1bS,4aR,7bS,8R,9R,9aS)-4a,7b,9-trihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1,1a,1b,4,4a,5,7a,7b,8,9-decahydro-9aH-cyclopropa[3,4]benzo[1,2-e]azulen-9a-yl acetate |
- |
|
2.3.1.30 | 11beta,12alpha,17-trihydroxy-5beta,9beta,10alpha-12,16-epoxyabieta-8(14),13(15)-dien-16-one |
- |
|
2.3.1.30 | 2-amino-9-(naphthalen-2-yl)-9H-purin-6-ol |
0.05 microg/microl showing 38% inhibition in the presence of 0.10 mM acetyl-CoA, binding to active site |
|
2.3.1.30 | 2-amino-9-naphthalen-2-yl-9H-purin-6-ol |
- |
|
2.3.1.30 | 3-oxo-2-phenyl-3,5-dihydro-2H-pyrazolo[3,4-d]thieno[2,3-b]pyridine-7-carboxylate |
most potent inhibitor, 0.05 microg/microl showing 50% inhibition in the presence of 0.10 mM acetyl-CoA, binding to active site, increasing Km, decreasing Vmax |
|
2.3.1.30 | 3-oxo-2-phenyl-3,5-dihydro-2H-pyrazolo[3,4-d]thieno[2,3-b]pyridine-7-carboxylic acid |
- |
|
2.3.1.30 | 4,10-dihydroxy-1,7-phenanthroline-3,9-dicarboxylate |
0.05 microg/microl showing 24% inhibition in the presence of 0.10 mM acetyl-CoA, binding to active site |
|
2.3.1.30 | 4,10-dihydroxy-1,7-phenanthroline-3,9-dicarboxylic acid |
- |
|
2.3.1.30 | 7beta,11alpha,17-trihydroxyhelioscopinolide E |
- |
|
2.3.1.30 | 8,11beta,14beta-trihydroxy-5beta,8alpha,9beta,10alpha,12beta-12,16-epoxyabiet-13(15)-en-16-one |
- |
|